Clinical Trials Logo

Clinical Trial Summary

This phase I trial studies the long-term side effects of the continuation of oral ONC201 in treating patients with solid tumors that have spread to other places in the body who have previously benefited from receiving this drug. Oral ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To evaluate the long-term safety and tolerability of ONC201 (oral ONC201) administered orally in patients with advanced cancers.

SECONDARY OBJECTIVES:

I. To characterize pharmacokinetics of ONC201. II. To assess serum biomarkers of therapeutic response to ONC201. III. To assess preliminary antitumor activity of ONC201 as a single agent in advanced solid tumors.

OUTLINE:

Patients receive oral ONC201 orally (PO) on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02324621
Study type Interventional
Source Rutgers, The State University of New Jersey
Contact
Status Completed
Phase Phase 1
Start date February 20, 2015
Completion date October 23, 2018

See also
  Status Clinical Trial Phase
Completed NCT01450384 - Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00477607 - Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin Phase 2/Phase 3
Completed NCT02049593 - PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors Phase 1
Terminated NCT00938457 - Stereotactic Radiation Therapy in Treating Patients With Liver Metastases Phase 1/Phase 2
Suspended NCT01843413 - Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases N/A
Withdrawn NCT03789773 - Holographic Mm-Wave Imaging in Patients Undergoing Radiation Therapy N/A
Completed NCT00390156 - Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors Phase 1
Completed NCT00037804 - Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction Phase 1